<DOC>
	<DOCNO>NCT00068549</DOCNO>
	<brief_summary>This phase I trial study side effect best dose gemcitabine give together radiation therapy cisplatin treat patient cervical cancer spread beyond pelvis . Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining cisplatin gemcitabine may make tumor cell sensitive radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Radiation Therapy Plus Cisplatin Gemcitabine Treating Patients With Cervical Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine toxicity pelvic radiotherapy concurrent cisplatin gemcitabine patient cervical carcinoma limit pelvis . II . Determine maximum tolerate dose ( MTD ) gemcitabine combination cisplatin pelvic radiotherapy patient . SECONDARY OBJECTIVES : I . Determine progression-free overall survival patient treat gemcitabine MTD regimen . II . Determine site recurrence , local versus distant , patient treat regimen . OUTLINE : This multicenter , dose-escalation study gemcitabine . Patients receive gemcitabine IV 30 minute cisplatin IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 absence disease progression unacceptable toxicity . Patients also undergo external whole pelvis radiotherapy daily day 1-5 , 8-13 , 15-20 , 22-27 , 29-34 . After completion external beam radiotherapy , patient undergo intracavitary radiotherapy parametrial radiotherapy . The total elapse time completion radiotherapy 8 week . Cohorts 3-6 patient receive escalate dos gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm primary invasive carcinoma uterine cervix Previously untreated disease Any cell type Stage IB_2 , IIA , IIB , IIIA , IIIB , IVA Paraaortic lymph node negative radiologic evaluation biopsy CT scan suspicious adenopathy No known metastasis scalene node organ outside radiotherapy field Study enrollment within 8 week diagnosis Performance status GOG 02 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 time normal SGOT great 3 time normal Creatinine le 2.0 mg/dL No renal abnormality ( e.g. , pelvic kidney , horseshoe kidney , renal transplantation ) would require modification radiotherapy field No ureteral obstruction allow unless treat stent nephrostomy tube Not pregnant Fertile patient must use effective contraception No septicemia severe infection No circumstance would preclude study completion followup No malignancy within past 5 year except nonmelanoma skin cancer No prior cytotoxic chemotherapy No prior pelvic abdominal radiotherapy No prior therapy malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>